News

BE HEARD extension data underscore the importance of early diagnosis and treatment initiation to optimize long-term outcomes in hidradenitis suppurativa.

With 80% of trial participants being children, this analysis provides some of the most robust early-response data available for a non-steroidal topical in pediatric AD.

Read more on how to navigate all the opportunities at this year’s AAD meeting, which starts today in Denver, Colorado.

The GLODERM Pre–AAD meeting emphasized that global skin health progress now depends on translating policy into scalable, equitable care delivery.

At the pre-AAD meeting, Regina Benjamin, MD, MBA, discussed the role of clinicians as leaders in addressing social determinants of health, emphasizing prevention, education, and culturally responsive care.

In a patient with longstanding Hailey-Hailey disease, lebrikizumab was associated with rapid improvement in symptoms and quality of life.

These leaders are shaping the future of dermatology through their clinical expertise, research, and educational presentations.

Levy reflected on the importance of mentorship, collaboration, and the evolving landscape of pediatric dermatology at the Society for Pediatric Dermatology Pre-AAD Meeting.

Despite declining skin care sales post-pandemic, fragrance products remain strong, prompting increased investment from cosmetic companies.

The rise of at-home injectable trends is exposing patients to risks including infection, nerve damage, and potential systemic complications.

Guardrails and disclaimers are essential for responsible AI deployment in dermatology, according to Faranak Kamangar, MD.

Who is a woman who has shaped your life and career in dermatology? Hear stories from our experts as we celebrate Women's History Month 2026.

Targeted therapies are increasingly used earlier in treatment rather than being reserved for severe or refractory cases.

This review of the latest dermatological studies includes insights on vitiligo cultural beliefs, home-based phototherapy, digital search behavior in NSV patients, and more.

Misconceptions about vitiligo, including contagion and supernatural causation, remain prevalent in many regions and are linked to increased stigma.

Linda Stein Gold, MD, FAAD, shares her thoughts on FDA-approved, once-daily oral icotrokinra for teens and adults with moderate to severe plaque psoriasis, promising biologic-like results, strong safety, and earlier systemic escalation.

A study shows physician counseling boosts safe adherence and curbs misinformation-driven decisions, as pregnant women often stop skin treatments and experience worsened symptoms.

The upcoming trial will assess an injectable formulation of Xvie, distinct from its currently available topical counterpart.

Overall, the future of dermatology lies in integrating innovation with individualized, evidence-based, and patient-centered care.

IL-17 inhibitors are highly effective, but many patients still require switching due to treatment failure, loss of response, or intolerance.

Successful negotiation integrates compensation, productivity, procedural access, and autonomy to create a sustainable, well-valued clinical role.

PANP360 Immersive will deliver one-day, high-yield dermatology CME for NPs and PAs, featuring hands-on workshops, complex case strategies, and practical tips to optimize therapies.

In a striking finding, 97% of patients who had experienced no facial repigmentation whatsoever at week 24 demonstrated measurable F-VASI improvement after 104 weeks of continuous ruxolitinib cream use.

Twin experts reveal how dermatology and dentistry team up for facial aesthetics, early lesion detection, and safer care—from lasers to oral screenings.

Phase 2 APEX part A data showed zumilokibart maintained EASI-75 responses in 75–85% of week 16 responders at 1 year across quarterly and biannual dosing regimens.

Swanson and Silverberg explain why tween skin care trends harm barriers, and how clinicians can simplify routines and spot allergens.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

In case you missed it, this week we had news on the FDA's approval of icotrokinra, phase 3 ADorable-1 data supporting lebrikizumab, the sBLA acceptance of tildrakizumab for PsA, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.